MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)

被引：0
|
作者：
Schmoll, H. [1 ]
Cunningham, D. [2 ]
Sobrero, A. [3 ]
Karapetis, C. [4 ]
Rougier, P. [5 ]
Koski, S. L. [6 ]
Barker, P. [7 ]
Mookerjee, B. [7 ]
Robertson, J. [8 ]
van Cutsem, E. [9 ]
机构：
[1] Univ Halle Wittenberg, Dept Internal Med 4, Halle, Germany
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Osped San Martino Genova, Dept Med Oncol, Genoa, Italy
[4] Flinders Med Ctr, Adelaide, SA, Australia
[5] Hop Ambroise Pare, Boulogne Billancourt, France
[6] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[7] AstraZeneca, Wilmington, DE USA
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Univ Hosp Gasthuisberg, Dept Internal Med, B-3000 Louvain, Belgium
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [31] Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera A.
    Karapetis, Christos Stelios
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera
    Karapetis, Christos S.
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    Fischer, JuDee
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    CLINICAL COLORECTAL CANCER, 2014, 13 (03) : 156 - 163
  • [33] Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
    Lima, Caio M. Rocha
    Bayraktar, Soley
    Flores, Aurea M.
    MacIntyre, Jessica
    Montero, Alberto
    Baranda, Joaquina C.
    Wallmark, John
    Portera, Chia
    Raja, Rajiv
    Stern, Howard
    Royer-Joo, Stephanie
    Amler, Lukas C.
    CANCER INVESTIGATION, 2012, 30 (10) : 727 - 731
  • [34] Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
    Hoff, Paulo M.
    Hochhaus, Andreas
    Pestalozzi, Bernhard C.
    Tebbutt, Niall C.
    Li, Jin
    Kim, Tae Won
    Koynov, Krassimir D.
    Kurteva, Galina
    Pinter, Tamas
    Cheng, Ying
    van Eyll, Brigitte
    Pike, Laura
    Fielding, Anitra
    Robertson, Jane D.
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3596 - 3603
  • [35] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
    Graham, C. N.
    Hechmati, G.
    Hjelmgren, J.
    De Liege, F.
    Lanier, J.
    Knoof, A.
    Knox, H.
    Barber, B.
    de Pouvourville, G.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [36] Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/III rectal cancer receiving pre-operative chemoradiation
    Benson, Al Bowen
    Zhao, Fengmin
    Meropol, Neal J.
    Catalano, Paul J.
    Chakravarthy, Bapsi
    Flynn, Patrick J.
    Catalano, Robert B.
    Giantonio, Bruce J.
    Mitchell, Edith P.
    Haller, Daniel G.
    Leichman, Cynthia G.
    Petrelli, Nicholas J.
    Sinicrope, Frank A.
    Tepper, Joel E.
    Brierley, James D.
    Sigurdson, Elin R.
    Whittington, Richard M.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Hjelmgren, Jonas
    de Liege, Frederique
    Lanier, Julie
    Knox, Hediyyih
    Barber, Beth
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2791 - 2801
  • [38] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
    Yoshino, Takayuki
    Watanabe, Jun
    Shitara, Kohei
    Yasui, Hirofumi
    Ohori, Hisatsugu
    Shiozawa, Manabu
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Hihara, Masamitsu
    Soeda, Junpei
    Yamamoto, Kouji
    Akagi, Kiwamu
    Ochiai, Atsushi
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [39] Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma
    Ocean, Allyson J.
    Polite, Blase
    Christos, Paul
    Horvath, Lisa
    Hamilton, Anne
    Matulich, Daniel
    Chen, Helen X.
    Sparano, Joseph A.
    Kindler, Hedy L.
    CLINICAL COLORECTAL CANCER, 2010, 9 (05) : 290 - 296
  • [40] A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05)
    Yamaguchi, Tatsuro
    Tsuji, Akihito
    Sunakawa, Yu
    Nakamura, Masato
    Kochi, Mitsugu
    Denda, Tadamichi
    Shimada, Ken
    Tani, Satoshi
    Takagane, Akinori
    Kotaka, Masahito
    Kuramochi, Hidekazu
    Koike, Junichi
    Furushima, Kaoru
    Yonemura, Yutaka
    Negoro, Yuji
    Takinishi, Yasutaka
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345